Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies.
Location: United States, Texas, Houston
Employees: 11-50
Total raised: $144.4M
Founded date: 2004
Investors 6
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | Hercules C... | htgc.com |
| - | RA Capital... | racap.com |
| - | Perceptive... | perceptive... |
| - | Rapha Capi... | raphacap.c... |
| - | Solasta Ve... | solasta-ve... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 07.12.2021 | - | $35M | - |
| 27.08.2014 | Series C | $55M | - |
| 07.01.2014 | Series B | $34.4M | - |
| 08.03.2012 | Series B | $20M | - |
Mentions in press and media 15
| Date | Title | Description | Source |
| 07.12.2021 | Bellicum Announces Positive Interim Data from Phase 1/2 GoCA... | HOUSTON - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable ... | marketscre... |
| 06.12.2021 | Bellicum Announces Positive Interim Data from Phase 1/2 GoCA... | - Confirmed partial response observed in one patient in first cohort of metastatic castration-resist... | globenewsw... |
| 06.12.2021 | Bellicum Announces Positive Interim Data from Phase 1/2 GoCA... | - Confirmed partial response observed in one patient in first cohort of metastatic castration-resist... | marketscre... |
| 07.12.2020 | Amid a record bad year, Bellicum keeps taking its lumps as... | It’s been no less than a disastrous year for Houston biotech Bellicum Pharmaceuticals after... | endpts.com... |
| 23.02.2018 | Bellicum outlines a few quick steps the FDA wants before ... | Bellicum rocked investors at the end of last month with news that its “safer” lead cell therapy ... | endpts.com... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 27.08.2014 | Bellicum Pharmaceuticals Completes $55M Series C Financing | Bellicum Pharmaceuticals, Inc., a Houston, Texas-based biotechnology company focused on developing e... | finsmes.co... |
| 07.01.2014 | Texas' Bellicum gets $15M to expand work on gene 'switch' te... | Close to a decade after a pair of investigators from Baylor College of Medicine launched Bellicum Ph... | fiercebiot... |
| 07.01.2014 | Bellicum Pharmaceuticals Inks $34.4M in Series B | HOUSTON, TX, Bellicum Pharmaceuticals announced today that it has completed a second and final clo... | vcnewsdail... |
| 07.01.2014 | Bellicum Pharmaceuticals Secured Additional $14.7M in Series... | Bellicum Pharmaceuticals, a Houston, Texas-based developer of cell therapies to treat cancers and ot... | finsmes.co... |
Show more